{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:03:54Z","timestamp":1787943834137,"version":"build-2784847793"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-022-00672-y","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:04:12Z","timestamp":1650873852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"672_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/CEOR.S187409","volume":"11","author":"A Forsythe","year":"2019","unstructured":"Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B. Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. Clinicoecon Outcomes Res. 2019;11:87\u201398.","journal-title":"Clinicoecon Outcomes Res"},{"key":"672_CR4","doi-asserted-by":"crossref","unstructured":"Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, et al. Venetoclax combinations delay the time to deterioration of HRQol in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022; in press.","DOI":"10.1038\/s41408-022-00668-8"},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11899-019-00552-6","volume":"14","author":"KP Loh","year":"2019","unstructured":"Loh KP, Abdallah M, Kumar AJ, Neuendorff NR, Dahiya S, Klepin HD. Health-related quality of life and treatment of older adults with acute myeloid leukemia: a young international society of geriatric oncology review paper. Curr Hematol Malig Rep. 2019;14:523\u201335.","journal-title":"Curr Hematol Malig Rep."},{"key":"672_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ejh.13389","volume":"104","author":"R Stauder","year":"2020","unstructured":"Stauder R, Lambert J, Desruol-Allardin S, Savre I, Gaugler L, Stojkov I, et al. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. Eur J Haematol. 2020;104:476\u201387.","journal-title":"Eur J Haematol"},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/10428194.2019.1709838","volume":"61","author":"SA Buckley","year":"2020","unstructured":"Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun D, Walter RB, Lee SJ. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leuk Lymphoma. 2020;61:1158\u201367.","journal-title":"Leuk Lymphoma"},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2017.08.010","volume":"32","author":"SA Buckley","year":"2018","unstructured":"Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH. Patient-reported outcomes in acute myeloid leukemia: where are we now? Blood Rev. 2018;32:81\u20137.","journal-title":"Blood Rev"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00672-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:08:17Z","timestamp":1669234097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00672-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"26 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}